Search This Blog

Tuesday, July 23, 2019

FDA OKs Merck’s Humira biosimilar

The FDA has approved Merck’s (NYSE:MRK) HADLIMA (adalimumab-bwwd), a biosimilar to AbbVie’s (NYSE:ABBV) top seller Humira (adalimumab).
Posted by at

No comments:

Post a Comment

Note: Only a member of this blog may post a comment.

Subscribe to: Post Comments (Atom)